High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma
- PMID: 26329521
 - PMCID: PMC4694846
 - DOI: 10.18632/oncotarget.4688
 
High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma
Abstract
Increased or decreased expression of LIF receptor (LIFr) has been reported in several human cancers, including skin cancer, but its role in melanoma is unknown. In this study, we investigated the expression pattern of LIFr in melanoma and assessed its prognostic value. Using tissue microarrays consisting of 441 melanomas and 96 nevi, we found that no normal nevi showed high LIFr expression. LIFr staining was significantly increased in primary melanoma compared to dysplastic nevi (P = 0.0003) and further increased in metastatic melanoma (P = 0.0000). Kaplan-Meier survival curve and univariate Cox regression analyses showed that increased expression of LIFr was correlated with poorer 5-year patient survival (overall survival, P = 0.0000; disease-specific survival, P = 0.0000). Multivariate Cox regression analyses indicated that increased LIFr expression was an independent prognostic marker for primary melanoma (P = 0.036). LIFr knockdown inhibited melanoma cell migration in wound healing assays and reduced stress fiber formation. LIFr knockdown correlated with STAT3 suppression, but not YAP, suggesting that LIFr activation might stimulate melanoma cell migration through the STAT3 pathway. Our data indicate that strong LIFr expression identifies potentially highly malignant melanocytic lesions at an early stage and LIFr may be a potential target for the development of early intervention therapeutics.
Keywords: LIFr; biomarker; cell migration; melanoma.
Conflict of interest statement
K.M. is Chief Scientific Officer of Replicel Life Sciences Inc. All other authors state no conflict of interest.
Figures
              
              
              
              
                
                
                
              
              
              
              
                
                
                
              
              
              
              
                
                
                
              
              
              
              
                
                
                
              
              
              
              
                
                
                
              
              
              
              
                
                
                
              
              
              
              
                
                
                
              
              
              
              
                
                
                References
- 
    
- Turner RM, et al. Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma. Journal of Clinical Oncology. 2011;29:4641–4646. - PubMed
 
 - 
    
- Geller AC, et al. Reducing mortality in individuals at high risk for advanced melanoma through education and screening. Journal of the American Academy of Dermatology. 2011;65:S87–S94. - PubMed
 
 - 
    
- KellokumpuLehtinen P, et al. Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. International Journal of Cancer. 1996;66:515–519. - PubMed
 
 - 
    
- Kamohara H, et al. Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells. Involvement of regulation of LIF and its receptor expression. International Journal of Oncology. 2007;30:977–983. - PubMed
 
 
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
